A fluorescence resonance energy transfer biosensor and its application

Abstract

The invention discloses a fluorescence resonance energy transfer biosensor and its application. The sensor includes a first binding probe and a second binding probe; wherein, the first binding probe is hybridized with aptamer1 and block1 to form a double helix structure, both aptamer1 and block1 are DNA sequences; the 3' end of the aptamer1 sequence is modified with fluorescent molecule A , assemble a first PSA aptamer on the 5' end for binding the target prostate cancer antigen (PSA) site; the second binding probe is aptamer2, which is a DNA sequence; on the 3' end of the aptamer2 sequence Assemble a second PSA aptamer for binding to another site of the target substance PSA, and modify the fluorescent molecule B on the 5' end; in the presence of the target substance PSA, aptamer2 replaces block1 and hybridizes with aptamer1 to form a double helix structure , the fluorescent molecule A and the fluorescent molecule B are close to each other and form a strong fluorescence resonance energy transfer effect. The sensor is applied in the detection of serum prostate specific antigen PSA, and has the advantages of high sensitivity, simple detection process, low analysis cost, and good diagnostic accuracy of markers.

Description

technical field [0001] The invention belongs to the technical field of biosensors, in particular to a fluorescence resonance energy transfer biosensor and its application. Background technique [0002] Prostate cancer is one of the most common malignant tumors in urology. According to statistics, in the United States and Europe, the morbidity and mortality of prostate cancer rank first and second among male malignancies, respectively. Serum prostate-specific antigen (PSA) is produced by prostate epithelial cells and has strong organ specificity. As a tumor marker, PSA has been widely used clinically, which has significantly improved the detection rate of prostate cancer. [0003] Clinical biochemical tests generally require a small amount of samples, fast and accurate, and it is best to be able to perform high-throughput analysis. Currently, routine clinical biochemical analysis generally relies on immunoassays. Enzyme-linked immunoassay (ELISA), radioimmunoassay (RIA), ...

AI Technical Summary

Problems solved by technology

Although these methods have certain value for disease diagnosis, they have disadvantages such as long analysis and detection cycle, cumbersome operation steps, high cost, and low analysis throughput, which limit their further clinical application.

Images